Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Monday

Key Points

• Acumen is expected to report Q4 2025 results before the market opens on Monday, March 30, with analysts forecasting an EPS loss of ($0.50); the company lists a conference call for Thursday, March 26, 2026 at 8:00 AM ET.
• Shares opened at $2.68 and were reported down 8.4%, giving the company a market cap of about $162.1 million (12‑month range $0.86–$3.60); insiders have sold 149,818 shares in the last 90 days, including CEO Daniel O’Connell’s sale of 37,755 shares.
• Analysts show a consensus rating of “Moderate Buy” with an average price target of $7.00 (five Buy ratings, one Sell), and institutional investors own roughly 71% of the stock.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) will likely be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.50) per share for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:00 AM ET.

Acumen Pharmaceuticals Trading Down 8.4%

NASDAQ ABOS opened at $2.68 on Monday. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.29. The business has a fifty day simple moving average of $2.62 and a 200 day simple moving average of $2.13. Acumen Pharmaceuticals has a 12 month low of $0.86 and a 12 month high of $3.60. The firm has a market capitalization of $162.09 million, a P/E ratio of -1.21 and a beta of 0.20.

Insider Buying and Selling

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 37,755 shares of the business's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $1.99, for a total value of $75,132.45. Following the transaction, the chief executive officer owned 619,982 shares of the company's stock, valued at approximately $1,233,764.18. The trade was a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 149,818 shares of company stock worth $285,057 in the last 90 days. Company insiders own 7.10% of the company's stock.

Institutional Investors Weigh In On Acumen Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ABOS. Jacobs Levy Equity Management Inc. purchased a new position in shares of Acumen Pharmaceuticals in the 3rd quarter worth about $27,000. Marex Group plc purchased a new stake in Acumen Pharmaceuticals during the second quarter worth about $39,000. Marshall Wace LLP purchased a new stake in Acumen Pharmaceuticals during the fourth quarter worth about $44,000. AQR Capital Management LLC bought a new stake in Acumen Pharmaceuticals in the first quarter worth about $46,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Acumen Pharmaceuticals in the fourth quarter worth about $47,000. 71.01% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on ABOS. BTIG Research upped their target price on shares of Acumen Pharmaceuticals from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, March 16th. Wall Street Zen lowered shares of Acumen Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Acumen Pharmaceuticals in a report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Acumen Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $7.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.

The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.